Cancer immunotherapy 

Developmental therapeutics

COVID-19 and cancer

Breast cancer 

Dr Yada Kanjanapan is a Medical Oncologist at The Canberra Hospital, and Clinical Senior Lecturer at the Australian National University. Her clinical sub-specialties are in breast and gynaecological cancers, melanoma and developmental therapeutics. 

Dr Kanjanapan has expertise in cancer immunotherapy and early-phase clinical trials through a two-year fellowship at the Princess Margaret Cancer Centre, Toronto, Canada. Her research track record includes leading a number of completed projects, in areas such as hypergrogressive disease in immunotherapy, and kinetics of immune-related adverse events in relation to dose-limiting toxicity determination. She has also been a clinical investigator in multiple early-phase trials. 

Dr Kanjanapan also has an interest in the COVID-19 pandemic with regards to impact on oncological care and outcome in cancer patients. She has written a perspective piece on “Considerations for cancer immunotherapy during the COVID-19 pandemic”, published in the Medical Journal of Australia. She is the lead author in the Medical Oncology Group of Australia Position Statement on COVID-19 vaccination in patients with solid tumours. Dr Kanjanapan is currently leading the EVEREST (Evaluation of COVID-19 Vaccination Efficacy and Rare Events in Solid Tumours) study at The Canberra Hospital, in collaboration with the Australian National University. 

Publications list: 

https://scholar.google.com.au/citations?user=htt7hwwAAAAJ&hl=en 

EVEREST: Evaluation of COVID-19 Vaccination Efficacy and Rare Events in Solid Tumours 
Collaboration between The Canberra Hospital and Australian National Universtiy on 
Assessment of antibody response to COVID-19 vaccination in people with solid tumours
and substudy investigating vaccine-mediated generation of anti-platelet factor 4 PF4 antibody 
(Principal Investigator) 

Analysis of immune correlates with tumour growth rate in solid cancers treated with immunotherapy- study of hyperprogressive disease from immune checkpoint inhibitor therapy (Principal Investigator) 

Implementation of a nurse-enabled, shared-care follow-up model for early breast cancer survivors: The IBIS-Survivorship Study (Sub-investigator)